BioHaven hopes to soothe Chinese headaches with Shanghai subsidiary
Capitalizing on the burgeoning biopharma interest in China, neuro-focused drug developer BioHaven $BHVN is setting up shop in Shanghai with a subsidiary called BioShin that will be tasked with shepherding the Connecticut-based company’s arsenal of late-stage migraine and neurology products in markets across the Asia-pacific region.
BioHaven, which earlier this week said it had submitted a US application to market a sublingual formulation of the ALS drug riluzole, is gearing up to report key data from a pivotal late-stage trial testing its acute migraine drug, rimegepant, before the end of the year in the United States. The company’s interest is China is not unexpected, given that large swathes of the region’s immense population suffer from migraine and other central nervous system disorders, although patients have not benefited from the heady pace of medical innovation their US counterparts have enjoyed.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.